FDA Modernization Act 3.0: The role of high throughput capacities in Relevant NAM Drug Development
The recent passage of the FDA Modernization Act 3.0 by the U.S. House represents another major step toward the regulatory acceptance of New Approach Methodologies (NAMs), including organoids, organ-on-chip systems, and other human-relevant technologies. The legislation directs the FDA to update regulations that still reference animal testing and further supports the agency's transition toward modern, scientifically valid alternatives. [fiercebiotech.com]
As an organoid expert since its beginning, I believe the discussion is no longer about whether organoids will become part of mainstream drug development. The real challenge is ensuring that organoid-based models deliver the standardization, reproducibility, scalability, and predictive power required for pharmaceutical R&D and regulatory decision-making.
Traditional preclinical in vitro models each offer distinct advantages but also significant limitations. 2D cell culture systems provide the high-throughput capacity required for early-stage screening and large-scale compound testing but are based on an oversimplified biology. Conventional first-generation organoid models provide greater physiological relevance but often generate data from individual organoids strictly separated in plastic cavities with significant variability in size, morphology, and growth behavior. These limitations can reduce translational value and make study-to-study comparisons difficult.
To unlock the full potential of organoid-based drug development, the industry requires solutions that combine biological relevance with industrial-grade standardization. The validated 3D CoSeedis™ Humanized Multi-Organoid Technology from abc biopply addresses this challenge by enabling the formation of highly standardized micro-tissues consisting of hundreds of interacting organoids under controlled conditions. By generating collective multi-organoid statistics rather than relying on a limited number of individual organoids, the platform significantly improves reproducibility, assay robustness, and translational relevance. This allows researchers to obtain more reliable data for efficacy, safety, toxicity, resistance, and biomarker studies while maintaining the complexity needed for next-generation New Approach Methodologies (NAMs).
As regulators increasingly embrace NAM-generated data, the industry will need solutions that are not only animal-free but also capable of generating robust and actionable evidence.
I am convinced that validated multi-organoid systems will play a key role in bridging the gap between scientific innovation and regulatory acceptance.
The future of preclinical development is not simply animal-free.
It is human-relevant, standardized, reproducible, and predictive.